ライフサイエンスコーパス: plasminogen activator inhibitor

1 bronectin 1 (P<0.0001), perforin (P=0.0002), plasminogen activator inhibitor 1 (P=0.0002), transformi

2 D-dimer, tissue plasminogen activator (tPA), plasminogen activator inhibitor 1 (PAI-1) and platelets.

3 HOE-140 also abolished the increase in plasminogen activator inhibitor 1 (PAI-1) antigen observ

4 The concentration of the main TPA inhibitor plasminogen activator inhibitor 1 (PAI-1) controlled bot

5 the protective and proliferative effects of plasminogen activator inhibitor 1 (PAI-1) deficiency aft

6 Plasminogen activator inhibitor 1 (PAI-1) is a serpin in

7 Transcriptional regulation of plasminogen activator inhibitor 1 (PAI-1) is of particul

8 pathway and augmented tissue factor (TF) and plasminogen activator inhibitor 1 (PAI-1) levels in veno

9 c TGF-beta1 mRNA, tissue hydroxyproline, and plasminogen activator inhibitor 1 (PAI-1) levels were si

10 potent and selective synthetic antagonist of plasminogen activator inhibitor 1 (PAI-1) that preserved

11 (MS, n = 20; control, n = 10), expression of plasminogen activator inhibitor 1 (PAI-1), a key enzyme

12 hich H. pylori upregulates the expression of plasminogen activator inhibitor 1 (PAI-1), a member of t

13 of JNK and p38 as well as the expression of plasminogen activator inhibitor 1 (PAI-1), a TGF-beta-re

14 D-dimer, tissue plasminogen activator (tPA), plasminogen activator inhibitor 1 (PAI-1), and platelets

15 diated proteolysis, which is counteracted by plasminogen activator inhibitor 1 (PAI-1), another secre

16 vator (tPA) and its physiological inhibitor, plasminogen activator inhibitor 1 (PAI-1), in Puumala ha

17 with diabetes experience elevated levels of plasminogen activator inhibitor 1 (PAI-1), regardless of

18 The aim of this study is to evaluate serum plasminogen activator inhibitor 1 (PAI-1), tumor necrosi

19 Furthermore, inhibition of plasminogen activator inhibitor 1 (PAI-1), which was the

20 VFA and higher plasma IL-6, adiponectin, and plasminogen activator inhibitor 1 (PAI-1).

21 isolated a high-quality DNA aptamer pair for plasminogen activator inhibitor 1 (PAI-1).

22 ral function for the gene SERPINE1, encoding plasminogen activator inhibitor 1 (PAI-1).

23 Plasminogen activator inhibitor 1 (PAI-1/serpinE1) can b

24 led to upregulate the fibrinolysis inhibitor plasminogen activator inhibitor 1 (Serpine1, also known

25 protein M130, Fatty acid binding protein 4, Plasminogen activator inhibitor 1 and Insulin-like growt

26 owed less fibrosis and blocked expression of plasminogen activator inhibitor 1 and osteopontin 1.

27 Transcriptional changes in the Tgf-beta1 and plasminogen activator inhibitor 1 gene products were mea

28 Increased activated plasminogen activator inhibitor 1 had a strong associati

29 king BDNF maturation in the hippocampus with plasminogen activator inhibitor 1 hinders the persistenc

30 s and levels of the coagulation intermediary plasminogen activator inhibitor 1 in three mouse models

31 plasminogen activator and elevated levels of plasminogen activator inhibitor 1 were observed.

32 as observed, but a trend toward lower plasma plasminogen activator inhibitor 1 with higher excretion

33 ent with earlier reports (thrombomodulin and plasminogen activator inhibitor 1), and 15 were new disc

34 ion of inflammatory mediators such as PAI-1 (plasminogen activator inhibitor 1), suggesting that gluc

35 Tests for FXI and FXII activity, plasminogen activator inhibitor 1, and activated partial

36 receptor 2, urokinase plasminogen activator, plasminogen activator inhibitor 1, and certain multipara

37 asminogen activators, a relatively decreased plasminogen activator inhibitor 1, and decreased levels

38 lammatory cytokines such as TNF-alpha, IL-6, plasminogen activator inhibitor 1, and IL-1beta.

39 1-mediated induction of fibronectin, Snail1, plasminogen activator inhibitor 1, and matrix metallopro

40 lammatory markers were then studied (sCD40L, plasminogen activator inhibitor 1, antithrombin III, and

41 whereas downregulation of thrombomospondin, plasminogen activator inhibitor 1, or connective tissue

42 tor, but did not influence thrombomospondin, plasminogen activator inhibitor 1, or connective tissue

43 lesterol, P < .001; triglycerides, P < .001; plasminogen activator inhibitor 1, P for trend = .04; an

44 Increased transcription of the genes for plasminogen activator inhibitor 1, Tgf-beta1, Tgf-beta-i

45 Plasminogen activator inhibitor 1, vascular cell adhesio

46 r slows down matrix degradation by increased plasminogen activator inhibitor 1.

47 tor and histidine-rich glycoprotein, but not plasminogen activator inhibitors 1 and 2.

48 It is well-established that complexes of plasminogen-activator inhibitor 1 (PAI-1) with its targe

49 asma tissue plasminogen activator (t-PA) and plasminogen-activator inhibitor 1 antigen and activity c

50 aused similar (p = NS) increases in inactive plasminogen-activator inhibitor 1 in both smokers and no

51 the role of the serine proteinase inhibitor plasminogen activator inhibitor -1 (PAI-1) in facilitati

52 in complex, tissue plasminogen activator and plasminogen activator inhibitor-1 (markers for fibrinoly

53 combined therapy attenuated the formation of plasminogen activator inhibitor-1 (p < 0.05), IL-1beta,

54 Higher plasminogen activator inhibitor-1 (p = 0.002), E-selecti

55 Similarly, higher plasminogen activator inhibitor-1 (p = 0.007) and S100B

56 Plasminogen activator inhibitor-1 (P=0.014), interleukin

57 n), factor VII G10976A, prothrombin G20210A, plasminogen activator inhibitor-1 (PAI-1) [-675] 4G/5G,

58 ay inhibitor (TFPI) expression and increased plasminogen activator inhibitor-1 (PAI-1) activity in th

59 ide new evidence that both overexpression of plasminogen activator inhibitor-1 (PAI-1) and elevated c

60 catabolism is increased after inhibition of plasminogen activator inhibitor-1 (PAI-1) and may consti

61 ve systematically examined the affinities of plasminogen activator inhibitor-1 (PAI-1) and proteinase

62 l transition (EMT), TNBC cells could produce plasminogen activator inhibitor-1 (PAI-1) and stimulate

63 n effects, including increased production of plasminogen activator inhibitor-1 (PAI-1) and tissue fac

64 ze the binding interfaces of urokinase (uPA):plasminogen activator inhibitor-1 (PAI-1) and uPA:plasmi

65 Concentrations of OPN, as well as plasminogen activator inhibitor-1 (PAI-1) and vascular e

66 intimal growth through early upregulation of plasminogen activator inhibitor-1 (PAI-1) and, subsequen

67 mostatic markers of endothelial dysfunction, plasminogen activator inhibitor-1 (PAI-1) antigen, and v

68 ctivatable fibrinolysis inhibitor (TAFI) and plasminogen activator inhibitor-1 (PAI-1) are causal fac

69 Vitronectin and plasminogen activator inhibitor-1 (PAI-1) are important

70 Vitronectin and plasminogen activator inhibitor-1 (PAI-1) are proteins t

71 In vitro, TSP1 acutely induces expression of plasminogen activator inhibitor-1 (PAI-1) by monocytic c

72 asure tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) by real-time P

73 The inactivation of plasminogen activator inhibitor-1 (PAI-1) by the small m

74 ons between genetic variants and circulating plasminogen activator inhibitor-1 (PAI-1) concentration,

75 adherin and induced Snail1, fibronectin, and plasminogen activator inhibitor-1 (PAI-1) expression.

76 onsensus XRE (NC-XRE) in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene that recr

77 Plasminogen activator inhibitor-1 (PAI-1) has been impli

78 epidermal growth factor receptor (EGFR) and plasminogen activator inhibitor-1 (PAI-1) have a shorter

79 Although the involvement of plasminogen activator inhibitor-1 (PAI-1) in fibrotic di

80 Basal expression of plasminogen activator inhibitor-1 (PAI-1) in human and m

81 ited MKK3-p38 kinase-dependent expression of plasminogen activator inhibitor-1 (PAI-1) in lung, there

82 Recent studies suggest a crucial role for plasminogen activator inhibitor-1 (PAI-1) in mediating s

83 fect of intracerebroventricular injection of plasminogen activator inhibitor-1 (PAI-1) in rat pups su

84 Levels of plasminogen activator inhibitor-1 (PAI-1) increased sign

85 en activator (uPA), its receptor (uPAR), and plasminogen activator inhibitor-1 (PAI-1) into the early

86 Plasminogen activator inhibitor-1 (PAI-1) is a biomarker

87 Plasminogen activator inhibitor-1 (PAI-1) is a serine pr

88 Plasminogen activator inhibitor-1 (PAI-1) is an importan

89 Plasminogen activator inhibitor-1 (PAI-1) is increased i

90 Plasminogen activator inhibitor-1 (PAI-1) is known to mo

91 Plasminogen activator inhibitor-1 (PAI-1) is known to pr

92 Plasminogen activator inhibitor-1 (PAI-1) is the key end

93 Plasminogen activator inhibitor-1 (PAI-1) is the main in

94 okinase-type plasminogen activator (uPA) and plasminogen activator inhibitor-1 (PAI-1) levels in the

95 he morning surge of the prothrombotic factor plasminogen activator inhibitor-1 (PAI-1) observed in hu

96 gands specific to alpha-helix F (alphaHF) of plasminogen activator inhibitor-1 (PAI-1) on the stoichi

97 king p53 (p53-/-) express minimal amounts of plasminogen activator inhibitor-1 (PAI-1) protein as wel

98 TGF-beta1 activity was evaluated using a plasminogen activator inhibitor-1 (PAI-1) reporter trans

99 glomerular fibrin deposition and glomerular plasminogen activator inhibitor-1 (PAI-1) staining than

100 iation of a gain-of-function polymorphism in plasminogen activator inhibitor-1 (PAI-1) with airway ob

101 Elevated levels of plasminogen activator inhibitor-1 (PAI-1), a potent inhi

102 Deficiency in plasminogen activator inhibitor-1 (PAI-1), an endogenous

103 t gene SERPINE1 that is encoding the protein plasminogen activator inhibitor-1 (PAI-1), an establishe

104 Plasma and tissue levels of plasminogen activator inhibitor-1 (PAI-1), an inhibitor

105 y expressed increased basal levels of SPARC, plasminogen activator inhibitor-1 (PAI-1), and active be

106 , vascular endothelial growth factor (VEGF), plasminogen activator inhibitor-1 (PAI-1), and endotheli

107 NADPH oxidases (NOXs), and fibrotic markers, plasminogen activator inhibitor-1 (PAI-1), and fibronect

108 VEGF, plasminogen activator inhibitor-1 (PAI-1), and pigment e

109 nase-9 (MMP-9), tumor necrosis factor-alpha, plasminogen activator inhibitor-1 (PAI-1), and urinary o

110 factor receptor (EGFR), p53] and subsequent plasminogen activator inhibitor-1 (PAI-1), connective ti

111 ese changes paralleled reduced expression of plasminogen activator inhibitor-1 (PAI-1), PDGF-B (PDGF-

112 ed for seven adipokines-adiponectin, leptin, plasminogen activator inhibitor-1 (PAI-1), resistin, hep

113 In infected mice that overexpress plasminogen activator inhibitor-1 (PAI-1), S. aureusclfA

114 ctor receptors (sTNFR-I and -II), protein C, plasminogen activator inhibitor-1 (PAI-1), surfactant pr

115 investigated the relationship of ceramide to plasminogen activator inhibitor-1 (PAI-1), the primary i

116 Plasminogen activator inhibitor-1 (PAI-1), which inhibit

117 the inactivation of tPA and two chain uPA by plasminogen activator inhibitor-1 (PAI-1), which is pote

118 leomycin failed to induce miR-34a in p53- or plasminogen activator inhibitor-1 (PAI-1)-deficient mice

119 receptor type 4 (CXCR4) and upregulation of plasminogen activator inhibitor-1 (PAI-1).

120 and both proteases are inhibited rapidly by plasminogen activator inhibitor-1 (PAI-1).

121 e agent shields rt-PA against degradation by plasminogen activator inhibitor-1 (PAI-1).

122 een shown that ethanol induces activation of plasminogen activator inhibitor-1 (PAI-1).

123 asminogen activator (tPA), and up-regulating plasminogen activator inhibitor-1 (PAI-1).

124 tions and is characterized by high levels of plasminogen activator inhibitor-1 (PAI-1).

125 xia-inducible factor-1alpha (HIF-1alpha) and plasminogen activator inhibitor-1 (PAI-1).

126 eral eNOS interactors, including the protein plasminogen activator inhibitor-1 (PAI-1).

127 ata for the latency transition of the serpin plasminogen activator inhibitor-1 (PAI-1).

128 Polymorphisms in plasminogen activator inhibitor-1 (PAI-1, SERPINE1) and

129 l and extracellular matrix remodeling [e.g., plasminogen activator inhibitor-1 (PAI-1; serine proteas

130 cript, identified by mRNA profiling, encoded plasminogen activator inhibitor-1 (PAI-1; SERPINE1).

131 upling of TGF-beta to Smad2/3 activation and plasminogen activator inhibitor-1 (PAI1) expression, whi

132 the enzyme x inhibitor complex of tcu-PA and plasminogen activator inhibitor-1 (tcu-PA.PAI-1).

133 ), inflammation (IL-6), or antifibrinolysis (plasminogen activator inhibitor-1 [PAI-1]) contribute to

134 P], renin, aldosterone), hemostatic factors (plasminogen activator inhibitor-1 [PAI-1]), inflammation

135 ad decreased ADAMTS-13 activity, but similar plasminogen activator inhibitor-1 activity and prothromb

136 Plasminogen activator inhibitor-1 also induced neurite e

137 Higher circulating plasminogen activator inhibitor-1 and aldosterone levels

138 On backward elimination, plasminogen activator inhibitor-1 and aldosterone remain

139 Plasminogen activator inhibitor-1 and C-reactive protein

140 Adjusting for S100B did not alter plasminogen activator inhibitor-1 and E-selectin associa

141 mes and hyperfibrinolysis with low levels of plasminogen activator inhibitor-1 and high D-dimer level

142 and mRNA expression of profibrotic markers: plasminogen activator inhibitor-1 and monocyte chemotact

143 TGF-beta signaling through up-regulation of plasminogen activator inhibitor-1 and phosphorylation of

144 both murine models while decreasing alveolar plasminogen activator inhibitor-1 and promoting myofibro

145 Plasminogen activator inhibitor-1 and protein C had a sy

146 Measurement of plasminogen activator inhibitor-1 and protein-C levels m

147 nd was completely abrogated by the urokinase plasminogen activator inhibitor-1 and serine protease in

148 ass index, such that the increased levels of plasminogen activator inhibitor-1 and soluble VCAM-1 ass

149 odest phenotypes, but mice deficient in both plasminogen activator inhibitor-1 and thrombin-activatab

150 ed expression of the prothrombotic molecules plasminogen activator inhibitor-1 and tissue factor (TF)

151 sal expression of alpha-smooth muscle actin, plasminogen activator inhibitor-1 and transforming growt

152 Preincubation of vitronectin with plasminogen activator inhibitor-1 eliminated its ability

153 tion, proliferation, collagen synthesis, and plasminogen activator inhibitor-1 expression in cardiac

154 with increased alpha-smooth muscle actin and plasminogen activator inhibitor-1 expression.

155 e liver by 2 hours, and the concentration of plasminogen activator inhibitor-1 in plasma increased be

156 easurement of plasma levels of protein C and plasminogen activator inhibitor-1 in plasma samples that

157 h enalapril or losartan also decreased renal plasminogen activator inhibitor-1 in TSLPtg mice, assess

158 s by infusion of blocking antibodies against plasminogen activator inhibitor-1 led to decreased lung-

159 ctivity were decreased due to an increase in plasminogen activator inhibitor-1 levels in transfusion-

160 matrix metalloproteinase (MMP)-8, MMP-9, and plasminogen activator inhibitor-1 levels were determined

161 eline protein-C levels were low and baseline plasminogen activator inhibitor-1 levels were elevated i

162 nce of circulating alteplase and recovery of plasminogen activator inhibitor-1 levels within 2 hours

163 e (including procollagen I, TGF-beta(1), and plasminogen activator inhibitor-1 mRNA), suggesting that

164 Mice deficient in plasminogen activator inhibitor-1 or thrombin-activatabl

165 ation of Smads 2 and 3 and activation of the plasminogen activator inhibitor-1 promoter (in NRP-154 a

166 sed transforming growth factor-beta-mediated plasminogen activator inhibitor-1 promoter activity in o

167 pitation showed reduced Smad3 binding to the plasminogen activator inhibitor-1 promoter in PTCs treat

168 on involves a functional polymorphism of the plasminogen activator inhibitor-1 promoter region and me

169 y reduced transactivation potential with the plasminogen activator inhibitor-1 promoters and behaved

170 tissue inhibitor of metalloproteinase-1 and plasminogen activator inhibitor-1 secretion in MDA-MB-23

171 S-1 peptide had increased efficacy in plasminogen activator inhibitor-1 serpin-deficient trans

172 of protein C and increased plasma levels of plasminogen activator inhibitor-1 that are independent r

173 addition, the use of exosites by maspin and plasminogen activator inhibitor-1 to indirectly affect p

174 mediated connective tissue growth factor and plasminogen activator inhibitor-1 up-regulation.

175 In contrast, both LOX-1 and CD32 mediate plasminogen activator inhibitor-1 upregulation in arteri

176 ed to augmented pressure (P=0.0003), whereas plasminogen activator inhibitor-1 was positively associa

177 mponents (analyzed as continuous variables), plasminogen activator inhibitor-1 was significantly and

178 Changes in interleukin-1B and plasminogen activator inhibitor-1 were apparent 24 hours

179 mplexes, plasminogen activator activity, and plasminogen activator inhibitor-1 were determined by mea

180 Falpha, leptin, adiponectin, fibrinogen, and plasminogen activator inhibitor-1 were determined.

181 variate analysis, lower protein C and higher plasminogen activator inhibitor-1 were strong independen

182 vation with pan-arterial vascular stiffness, plasminogen activator inhibitor-1 with central vascular

183 of prometastatic (i.e. cyclooxygenase-2 and plasminogen activator inhibitor-1) and prosurvival (i.e.

184 oatrial natriuretic peptide, fibrinogen, and plasminogen activator inhibitor-1) in nonobese Framingha

185 There was a 51.8% net decrease in PAI-1 (plasminogen activator inhibitor-1), a 12.1% net decrease

186 (D-dimer, tissue-type plasminogen activator, plasminogen activator inhibitor-1), and inflammation (in

187 eactive protein), hemostasis (fibrinogen and plasminogen activator inhibitor-1), neurohormonal activa

188 C-reactive protein), hemostasis (D-dimer and plasminogen activator inhibitor-1), neurohormonal activi

189 s is either weak (interleukin-8) or delayed (plasminogen activator inhibitor-1).

190 crease in interleukin-8, a 21.4% decrease in plasminogen activator inhibitor-1, a 51.3% decrease in t

191 n of CAGE led to the decreased expression of plasminogen activator inhibitor-1, a TGFbeta-responsive

192 evented CRP-induced arteriolar expression of plasminogen activator inhibitor-1, a thrombogenic protei

193 c peptide) and lower blood concentrations of plasminogen activator inhibitor-1, aldosterone, C-reacti

194 -regulation of the production and release of plasminogen activator inhibitor-1, an inhibitor of the p

195 to a reduction in the proteolytic inhibitor, plasminogen activator inhibitor-1, and an associated thr

196 ndividually, C-reactive protein, fibrinogen, plasminogen activator inhibitor-1, and ARR were related

197 ines, including migration inhibitory factor, plasminogen activator inhibitor-1, and C-C motif chemoki

198 1+2, fibrinogen, thrombomodulin, protein C, plasminogen activator inhibitor-1, and D-dimers.

199 protein cholesterol, albumin excretion rate, plasminogen activator inhibitor-1, and hemoglobin A1c le

200 d2 phosphorylation, normalized expression of plasminogen activator inhibitor-1, and mitigated PH and

201 lammatory markers, e.g., C-reactive protein, plasminogen activator inhibitor-1, and other cytokines,

202 s of insulin, triglycerides, blood pressure, plasminogen activator inhibitor-1, and the ratio of tota

203 pression of interleukin-6, thrombospondin-1, plasminogen activator inhibitor-1, and tissue factor, wh

204 associated with inhibition of TGF-beta1 and plasminogen activator inhibitor-1, and with a significan

205 6, endothelin-1, matrix metalloproteinase-9, plasminogen activator inhibitor-1, Bax and caspase-3, pr

206 ded natriuretic peptides, cardiac troponins, plasminogen activator inhibitor-1, D-dimer, fibrinogen,

207 We measured plasma concentrations of plasminogen activator inhibitor-1, E-selectin, and angio

208 flammation (C-reactive protein), hemostasis (plasminogen activator inhibitor-1, fibrinogen), neurohor

209 etic peptide and B-type natriuretic peptide, plasminogen activator inhibitor-1, fibrinogen, and homoc

210 on of genes downstream of Smad2/3, including plasminogen activator inhibitor-1, fibronectin, and conn

211 assays for 6 biomarkers (C-reactive protein, plasminogen activator inhibitor-1, homocysteine, aldoste

212 3, high urokinase-type plasminogen activator/plasminogen activator inhibitor-1, hormone receptor (HR)

213 d expression of TGF-beta downstream targets (plasminogen activator inhibitor-1, parathyroid hormone-r

214 (+/+) mice contained plasminogen activators, plasminogen activator inhibitor-1, plasminogen, and alph

215 asmin complex, tissue plasminogen activator, plasminogen activator inhibitor-1, protein C, antithromb

216 ng strand 1C observed in a prelatent form of plasminogen activator inhibitor-1, since the (1)H NMR sp

217 matrix metalloproteinase-9, myeloperoxidase, plasminogen activator inhibitor-1, soluble E-selectin, s

218 tronectin was enhanced by uPA and blocked by plasminogen activator inhibitor-1, the latter approach a

219 tasis, including TWIST1, fibronectin (FN)-1, plasminogen activator inhibitor-1, urokinase-type plasmi

220 dothelin-1, tissue plasminogen activator and plasminogen activator inhibitor-1, was depressed by expo

221 uinating enzyme, represses the expression of plasminogen activator inhibitor-1, which is critical in

222 ependent connective tissue growth factor and plasminogen activator inhibitor-1-induced proliferative

223 y upregulating the serine protease inhibitor plasminogen activator inhibitor-1.

224 xpression of the endogenous Smad target gene plasminogen activator inhibitor-1.

225 ue growth factor, collagen-alpha1[Iota], and plasminogen activator inhibitor-1.

226 nd to S195A tPA that is already complexed to plasminogen activator inhibitor-1.

227 ants without affecting the protein levels of plasminogen activator inhibitor-1.

228 pus by inducing expression of its inhibitor, plasminogen activator inhibitor-1.

229 or pathway inhibitor, fibrinogen-like 1, and plasminogen activator inhibitor-1.

230 nectin, X-linked inhibitor of apoptosis, and plasminogen activator inhibitor-1.

231 e TSP-1 and decrease VEGF by reducing PAI-1 (plasminogen activator inhibitor-1/SERPINE1) levels.

232 in 6 patients, protein S deficiency in 4, a plasminogen-activator inhibitor-1 (PAI-1) deficiency in

233 orylation results in inducible expression of plasminogen activator inhibitor-2 (PAI-2), a member of t

234 egulation of genes encoding proteins such as plasminogen activator inhibitors and matrix metalloprote

235 n-10), coagulation (antithrombin, factor IX, plasminogen activator inhibitor, d-dimer, thrombin antit

236 lar matrix accumulation and increased PAI-1 (plasminogen activator inhibitor) expression.

237 covered roles for plasminogen activators and plasminogen activator inhibitors in these diseases provi

238 ones emerging (collagen-I, thrombospondin-I, plasminogen activator inhibitor, MMP1, 9, ADAMTS4, TIMP1

239 r, plasmin-alpha2-antiplasmin complexes, and plasminogen activator inhibitor) or the release of pro-

240 tissue factor pathway inhibitor, protein C, plasminogen activator inhibitor (PAI), and thrombin-anti

241 of urokinase plasminogen activator (uPA) and plasminogen activator inhibitor (PAI)-1 in 2 murine mamm

242 Recent studies demonstrating a role for plasminogen activator inhibitor (PAI)-1 in cholestatic l

243 8, macrophage chemoattractant protein-1, and plasminogen activator inhibitor (PAI)-1 mRNA (r >/= 0.46

244 effect on plaque growth, we used a truncated plasminogen activator inhibitor (PAI)-1 protein, rPAI-1(

245 hesion molecules, fibrinogen-like protein 2, plasminogen activator inhibitor (PAI)-1), secretion of p

246 1 bound the promoters of tissue factor (TF), Plasminogen Activator Inhibitor (PAI)-1, and NGF-1A Bind

247 y stage, and urinary cell levels of mRNA for plasminogen activator inhibitor (PAI)-1, vimentin, tissu

248 n 2, tissue plasminogen activator (tPA), and plasminogen activator inhibitor (PAI)-1.

249 ghly susceptible, whereas those deficient in plasminogen activator inhibitor (PAI-1) are resistant to

250 The 4G/5G polymorphism in the plasminogen activator inhibitor (PAI-1) gene impacts tra

251 sized that lower protein C and higher type 1 plasminogen activator inhibitor (PAI-1) levels in plasma

252 Plasminogen activator inhibitor (PAI-1) levels were quan

253 ) (by confocal microscopy), plasma levels of plasminogen activator inhibitor (PAI-1), and factor XIII

254 inogen activator, alpha2-antiplasmin, active plasminogen activator inhibitor (PAI-1), and fibrin form

255 chemotactic protein-1 (CCL2) (MCP-1), tissue plasminogen activator inhibitor (PAI-1), and regulated o

256 l inhibitor of plasminogen activator, type I plasminogen activator inhibitor (PAI-1), controls blood

257 connective tissue growth factor (CTGF), and plasminogen activator inhibitor (PAI-1).

258 ntal vascular-endothelial function [ratio of plasminogen-activator inhibitor (PAI) 1 to PAI-2 and mea

259 Plasminogen activator inhibitors (PAIs) 1 and 2 were als

260 se in adipocyte diameter (P = 0.048), plasma plasminogen activator inhibitor protein-1 (P = 0.019), v

261 s, including DNA-binding protein A, 9G8, and plasminogen activator inhibitor RNA-binding protein 1 (P

262 ptor annexin 2A as well as downregulation of plasminogen activator inhibitor serpine1 in myocardium a

263 Recently it has been demonstrated that plasminogen activator inhibitor serpins promote brain me

264 Plasminogen activator inhibitor type 1 (PAI-1) is a majo

265 Plasminogen activator inhibitor type 1 (PAI-1) is a seri

266 Surprisingly, addition of high dose plasminogen activator inhibitor type 1 (PAI-1) to bile d

267 cellular adhesion molecule 1 (ICAM1), F4/80, plasminogen activator inhibitor type 1 (PAI-1), and type

268 novel class of small molecule inhibitors for plasminogen activator inhibitor type 1 (PAI-1), represen

269 Similarly, addition of plasminogen activator inhibitor type 1 (SERPINE1) blocke

270 complex, plasmin-alpha2-antiplasmin complex, plasminogen activator inhibitor type 1 [PAI-1], D-dimer,

271 ng tissue-type plasminogen activator [t-PA], plasminogen activator inhibitor type 1 [PAI-I]), and car

272 Plasminogen activator inhibitor type 1 antigen and activ

273 y led to (1) lower plasma insulin; (2) lower plasminogen activator inhibitor type 1 antigen and activ

274 e examined effects of co-administration of a plasminogen activator inhibitor type 1 derived peptide,

275 dex, and urokinase plasminogen activator and plasminogen activator inhibitor type 1 in specific subgr

276 r and/or the tissue plasminogen activator-to-plasminogen activator inhibitor type 1 ratio tests, to a

277 mbosis and endothelial function (D-dimer and plasminogen activator inhibitor type 1), and microvascul

278 nogen activator antigen (known to track with plasminogen activator inhibitor type 1); and (3) lower C

279 Plasminogen activator inhibitor type 1, (PAI-1) the prim

280 r-alpha, monocyte chemoattractant protein-1, plasminogen activator inhibitor type 1, and macrophage p

281 roteins (mammalian target of rapamycin, SMA, plasminogen activator inhibitor type 1, and type I colla

282 sera expressed and released higher levels of plasminogen activator inhibitor type 1, reduced levels o

283 e plasminogen activator (uPA), its inhibitor plasminogen activator inhibitor type 1, uPA receptor (uP

284 tes and proposes a crucial upstream role for plasminogen activator inhibitor type 1-dependent regulat

285 SerpinB2 or plasminogen activator inhibitor type 2 (PAI-2) is highly

286 Here we show that depletion of plasminogen activator inhibitor type 2 (PAI-2), a serine

287 SerpinB2 (plasminogen activator inhibitor type 2) is constitutivel

288 cytoprotective, Rb-binding protein SerpinB2 (plasminogen activator inhibitor type 2) protects Rb from

289 ough down-regulation of thrombospondin-1 and plasminogen activator inhibitor type 2.

290 Increased levels of plasminogen activator inhibitor type I (PAI-1) have been

291 plasma tissue-type plasminogen activator and plasminogen activator inhibitor type I) was not influenc

292 However, adipose tissue expression of plasminogen activator inhibitor type-1 (PAI-1) and CD11

293 Plasminogen activator inhibitor type-1 (PAI-1) is a memb

294 Plasminogen activator inhibitor type-1 (PAI-1) is a seri

295 The serine proteinase inhibitor, plasminogen activator inhibitor type-1 (PAI-1), binds to

296 Plasminogen activator inhibitor type-1 (PAI-1; encoded b

297 Transcriptional up-regulation of the plasminogen activator inhibitor type-2 (PAI-2) gene is a

298 de, aldosterone, renin, fibrinogen, D-dimer, plasminogen-activator inhibitor type 1, and homocysteine

299 ne, renin, B-type natriuretic peptide (BNP), plasminogen-activator inhibitor type 1, fibrinogen, and

300 ddition, connective tissue growth factor and plasminogen activator inhibitor were downregulated, alon